top of page

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...
JMG Logo transparent.png
Executive Spotlights

UCB to Acquire Candid Therapeutics in Immunology Expansion Deal

  • May 6
  • 1 min read

Brussels, Belgium, May 3, 2026 (UCB) -- UCB has announced plans to acquire Candid Therapeutics to strengthen its immunology pipeline. The transaction will add novel T-cell engager therapies aimed at addressing complex immune-mediated diseases. The deal is intended to broaden UCB’s research capabilities and support development of next-generation biologic treatments.


Read full article here.

 
 
 

Recent Posts

See All
Novanta to Acquire Riverpoint Medical for $1.2B

Bedford, MA, June 9, 2026 (Novanta) -- Novanta has announced the acquisition of Riverpoint Medical to strengthen its healthcare and surgical solutions portfolio. The transaction expands Novanta’s ca

 
 
 

Comments


Life Science Headlines
bottom of page